Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...

The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...

BOCA RATON, FLORIDA - INmune Bio , Inc. (NASDAQ: NASDAQ:INMB), a clinical-stage biotechnology company with a market capitalization of $212.74 million, announced today its plans to submit regulatory ...

On June 2, 2024, Caribou issued a press release announcing that it had "presented updated clinical data from the ongoing ANTLER Phase 1 trial that [purportedly] indicates a single dose of CB-010 . . .

The Care PC trial is the first using a NK targeted biologic therapy. The Veteran received the “medium” dose of INKmune initiating the Phase II portion of the trial. “The INmune Bio study ...

Low- and middle-income countries are under-represented in research into the gut microbiome, and addressing this is key to understanding the link between gut-resident microorganisms and health.

The Care PC trial is the first using a NK targeted biologic therapy ... facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.

So what: If you purchased Caribou securities during the ... including preclinical research activities associated with the allogeneic CAR-NK platform; (3) the foregoing was likely to have a ...